What is Zacks Research's Forecast for Omnicell Q2 Earnings?

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Analysts at Zacks Research decreased their Q2 2025 earnings estimates for shares of Omnicell in a research note issued to investors on Wednesday, June 18th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.10 per share for the quarter, down from their prior estimate of $0.12. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.28 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.44 EPS, Q1 2027 earnings at ($0.03) EPS and FY2027 earnings at $0.88 EPS.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The firm had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. During the same period in the previous year, the company earned $0.03 EPS. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company reiterated an "overweight" rating and set a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Wall Street Zen upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Bank of America lifted their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Finally, Benchmark decreased their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell presently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Trading Up 0.3%

Shares of OMCL stock traded up $0.10 during trading hours on Monday, reaching $28.84. 445,990 shares of the stock were exchanged, compared to its average volume of 569,155. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.75. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13. The company's 50-day moving average price is $29.30 and its 200-day moving average price is $36.07. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 62.70 and a beta of 0.78.

Institutional Investors Weigh In On Omnicell

Large investors have recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Omnicell in the 4th quarter valued at about $37,000. Van ECK Associates Corp raised its stake in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell during the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. raised its stake in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after acquiring an additional 355 shares in the last quarter. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.